GlassScriptPhysician profile
Fawad H Rizvi
NPI 1700107349
$16,104.90
in general payments reported to CMS, 2019-2025
57 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,349 · 2020: $2,036 · 2021: $2,234 · 2022: $3,300 · 2023: $2,833 · 2024: $2,932 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,386 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,386.02 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $3,091.77 | 2020-2024 | Licart, Tirosint, Tirosint |
| Boston Scientific Corporation | $2,277.62 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $1,443.83 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Nevro Corp. | $1,109.25 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $735.50 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $699.57 | 2019-2023 | Ztlido |
| Allergan, INC. | $645.85 | 2019-2022 | |
| Abbott Laboratories | $558.98 | 2019-2024 | Proclaim |
| Amgen INC. | $452.78 | 2019-2021 | |
| Tersera Therapeutics LLC | $397.84 | 2019-2025 | Prialt |
| Nalu Medical, INC. | $394.28 | 2022-2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.04 | 2019-2024 | Relistor |
| Mdd US Operations, LLC | $324.48 | 2019-2020 | |
| Pfizer INC. | $309.54 | 2019-2024 | |
| Relievant Medsystems, INC. | $284.34 | 2021-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawad Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.